To cite this paper use one of the standards below:
Please log in to watch the video
Log inINTRODUCTION AND OBJECTIVES: Cancer is an increasingly prevalent disease that affects millions of people annually worldwide. Many efforts have been made by researchers in order to elucidate the mechanisms of this disease and thus to propose new therapeutic and prophylactic measures. Evidence has emerged that the biological effects of heparin are beyond anticoagulant activity. It has been demonstrated to have anti-inflammatory, anti-viral, anti-tumor effects. However, it is not possible to use it for these therapeutic purposes due to its potential hemorrhagic effect. Given this, new molecules have been researched with a view to getting over this obstacle. With this in mind, in our laboratory we were able to purify a fraction of bovine intestinal heparin with low anticoagulant activity (LABH). In this essay, our aim is to test this molecule for anti-metastatic activity. MATERIAL AND METHODS: We used the lung metastasis induced animal model due to intravenous injection into the tail vein of Lung Lewis Carcinoma (LLC) cells, in the amount of 300,000 cells/animal, in C57BL/6 wild type mice 10-12 weeks old. The animals were treated with 1 daily dose of LABH (N =10) at a dose of 20 mg/kg subcutaneously, the first dose occurring 1 hour before the administration of the LLC cells, and compared to the 0.9% saline group (N =11) and a group of healthy animals (N=5). The animals were followed for 3 weeks and, at the end of this period, the animals were sacrificed and the pulmonary metastatic foci counted. RESULTS AND CONCLUSION: During follow-up there was no behavioral change, bleeding or local adverse reactions related to LABH. There was no weight variation in relation to the group of healthy animals. In the pathological analysis by macroscopy, LABH was able to reduce the absolute number of animals affected by metastasis, as well as the number of metastatic foci per animal, expressing a relative risk reduction of 77%. Thus, we concluded that LABH demonstrated safety locally and systemically for multiple doses and also exhibited an effective anti-metastatic action. Further studies in other animal models and with other doses are needed in order to investigate the full potential benefit of this molecule.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper